Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
  • 4.9 (43)
  • EDUCATION
  • UPDATED SEMIMONTHLY
Blood Cancer Talks Podcast

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

  1. AUG 29

    Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt

    In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space.  Here are the key papers we discussed:  1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/ 2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/ 3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/ 4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/ 5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199

    42 min

  2. AUG 14

    Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

    In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/  2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  3. COMMANDS trial : Luspatercept  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract  4. IMerge trial: Imetelstat  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract

    43 min

  3. JUL 21

    Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds

    In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed:  1.     MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2.     REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3.     MAJIC PV study https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 4.     Cyto-PV Study https://www.nejm.org/doi/full/10.1056/NEJMoa1208500 5.     PROUD-PV and CONTINUATION-PV trials https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract 6.     RESPONSE clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa1409002 7.     Rusferitide in PV https://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

    57 min

  4. JUL 6

    Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

    In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:  1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library.ehaweb.org/eha/2024/eha2024-congress/4136516   2.     Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study): https://library.ehaweb.org/eha/2024/eha2024-congress/422343   3.     3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740   4.     ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515   5.     HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext   6.     Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268   7.      Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267

    48 min

  5. JUN 9

    Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin

    In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1.      Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0 2.     EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/ 3.     Predictors of un-sustained MRD-negativity in multiple myeloma:  a)     Secondary analysis of FORTE trial: https://pubmed.ncbi.nlm.nih.gov/38048557/ b)     Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials: https://pubmed.ncbi.nlm.nih.gov/38048552/ 4.     Kinetics of MRD resurgence and subsequent relapse in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34807986/ 5.     MRD2STOP trial (MRD-guided maintenance discontinuation): https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.106 6.     MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial): https://pubmed.ncbi.nlm.nih.gov/37506339/

    58 min

  6. MAY 29

    Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

    In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows:   ·       GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers.   §  https://www.nature.com/articles/s41375-018-0107-z   ·       MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis   §  https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed   ·       TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis   §  https://ashpublications.org/blood/article/142/Supplement%201/620/502738/Transform-1-A-Randomized-Double-Blind-Placebo   ·       MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study   §  https://ashpublications.org/blood/article/142/Supplement%201/628/502728/Pelabresib-in-Combination-with-Ruxolitinib-for   ·       XPORT-MF-034: Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

    1h 1m

  7. MAY 1

    Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

    In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation):  https://pubmed.ncbi.nlm.nih.gov/28742454/   2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/   3. Outcomes of lenalidomide maintenance stratified by cytogenetic subgroups (Secondary analysis of Myeloma XI): https://pubmed.ncbi.nlm.nih.gov/36564045/   4. Canadian real-world data on lenalidomide maintenance: https://pubmed.ncbi.nlm.nih.gov/33054120/   5. FORTE trial (Carfilzomib-Lenalidomide vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/34774221/   6. ATLAS trial (Carfilzomib-Lenalidomide-Dexamethasone vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/36642080/   7. Differential censoring and potential impact on PFS in ATLAS trial: https://pubmed.ncbi.nlm.nih.gov/37433885/   8. GEM2014 (Ixazomib-Lenalidomide-Dexamethasone vs Lenalidomide-Dexamethasone): https://ashpublications.org/blood/article-abstract/142/18/1518/497188   9. MASTER trial (MRD-guided treatment de-escalation): https://pubmed.ncbi.nlm.nih.gov/37776872/   10. Outcomes after MRD-guided treatment discontinuation (Secondary analysis of GEM2014MAIN trial): https://pubmed.ncbi.nlm.nih.gov/37506339/

    53 min

  8. APR 18

    Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal

    In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes:1.     IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ·        Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated ·        Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated ·        Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated ·        High risk: History of thrombosis (any age/genotype), or age >60 years with JAK2 mutation https://ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International                        2.    The MIPSS-ET provides points for: ·        Age > 60 years (3 points) ·        Adverse mutation (SF3B1/SRSF2/U2AF1/TP53) (2 points) ·        Male sex (1 point) ·        White blood cell count ≥11 × 10^9/L (1 point) ·        https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16380?sid=nlm%3Apubmed   3.    Aspirin   o   Is there a benefit of twice-daily aspirin dosing, especially in high-risk or JAK2-mutant disease? https://ashpublications.org/blood/article/136/2/171/454293/A-randomized-double-blind-trial-of-3-aspirin   4.     Cytoreduction in High-risk ET  Hydroxyurea: https://www.nejm.org/doi/full/10.1056/NEJM199504273321704   Pegylated interferon alfa   MPD-RC 112 Mascarenhas J et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood . 2022)  https://ashpublications.org/blood/article/139/19/2931/483404/A-randomized-phase-3-trial-of-interferon-vs   Anagrelide in ET https://ashpublications.org/blood/article/121/10/1720/31186/Anagrelide-compared-with-hydroxyurea-in-WHO   5.    Ruxolitinib   In a randomized study phase 2 study (MAJIC-ET), ruxolitinib treatment did not deliver better rates of hematological response than best-available therapy, although symptoms did improve.    ·        MAJIC-ET study which is a randomized phase 2 trial  ·        ET patients resistant/intolerant to HU were randomized to receive RUX or standard treatment (HU 71%, anagrelide 48%, IFN 40%). The primary study outcome was CR, defined by normal platelet and white cell counts and normal spleen size.   ·        At 1 year, response was achieved in 46% of patients in the RUX group and in 44% in the standard arm, without statistically significant difference between the two groups.   ·        In addition, no difference was observed in the rates of thrombosis, hemorrhage, and disease transformation after 2 years of follow-up.   ·        MRs were also uncommon. RUX was superior, however, in symptom control.  https://ashpublications.org/blood/article/130/17/1889/36509/Ruxolitinib-vs-best-available-therapy-for-ET

    35 min
See All (51)

Trailer

4.9
out of 5
43 Ratings

About

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

Information

  • Creator
    Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
  • Years Active
    2022 - 2024
  • Episodes
    51
  • Rating
    Clean
  • Copyright
    © 2024 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada